Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$255.5M
11M shares
52-week range
$5.26 – $25.52
92% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
www.biodesix.comNo one on the platform currently holds BDSX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 11,948 | $173.2K |
| Execution date | Ratio |
|---|---|
| 2025-09-15 | 1-for-20reverse |
No one on the platform has traded BDSX yet.
$BDSX Purchase by 10% owner: https://filingtracker.ai/filing/1021412/0000905148-26-003599?doc=form4.xml
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-5-biodesix-inc-stock/ $BDSX Biodesix Earnings Transcript
View on StockTwits ↗$BDSX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.71 up 55.62% YoY • Reported revenue of $26.86M up 34.18% YoY • Biodesix expects total revenue of $108-114 million for full year 2026, with the midpoint representing approximately 25% growth over 2025, and maintains gross margin guidance of approximately 80% for 2026.
View on StockTwits ↗$BDSX Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference https://marketwirenews.com/stock/bdsx/news/biodesix-to-participate-in-canaccord-genuity-s-46th--8701201533428978.html?utm_source=stocktwits
View on StockTwits ↗$BDSX scheduled a fireside chat at Canaccord Genuity's 46th Annual Growth Conference Aug 12.
View on StockTwits ↗$BDSX scheduled its Q2 2026 results release for August 5.
View on StockTwits ↗$BDSX this might actually have more in it than I thought
View on StockTwits ↗$BDSX https://anachart.com/wp-content/uploads/2026/06/1781791278_soc-img.jpg
View on StockTwits ↗#DILUTION Ameris Bancorp ($ABCB) files mixed securities shelf offering Babcock & Wilcox Enterprises ($BW) files for 11,657,221 share common stock offering by selling stockholders Biodesix ($BDSX) files for 375,000 share common stock offering by selling stockholders Galaxy Digital ($GLXY) files for resale of up to 265,061,636 shares of Class A common stock Ondas Inc. ($ONDS) filed prospectus supplement on May 22 to its effective registration statement on Form S-3ASR covering the resale from time to time by certain stockholders of 2,738,224 shares
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.